SGLT2 inhibitors improve cardiac function, reduce the progression of heart failure, and decrease cardiovascular risk in patients with type 2 diabetes mellitus.
Do SGLT2 inhibitors improve heart failure and left ventricular diastolic function in patients with type 2 diabetes mellitus?
SGLT2 inhibitors demonstrate cardioprotective potential by improving cardiac function and reducing heart failure progression in patients with type 2 diabetes mellitus.
This article investigates the effects of SGLT2 inhibitors on heart failure and left ventricular diastolic function in patients with type 2 diabetes mellitus. The study analyzes the pathophysiological relationship between diabetes and cardiovascular complications, focusing on diabetic cardiomyopathy and diastolic dysfunction. The impact of SGLT2 inhibitors on cardiac remodeling, myocardial relaxation, and heart failure symptoms was evaluated using clinical and echocardiographic parameters. The findings indicate that SGLT2 inhibitors improve cardiac function, reduce the progression of heart failure, and decrease cardiovascular risk. The results confirm the cardioprotective potential of these agents and support their use in the comprehensive management of patients with type 2 diabetes mellitus
Tursunaliyev et al. (Fri,) conducted a review in Type 2 diabetes mellitus with heart failure and left ventricular diastolic dysfunction. SGLT2 inhibitors was evaluated on Cardiac remodeling, myocardial relaxation, and heart failure symptoms. SGLT2 inhibitors improve cardiac function, reduce the progression of heart failure, and decrease cardiovascular risk in patients with type 2 diabetes mellitus.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: